If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
MEQUON, Wis., Aug. 6–(HSMN NewsFeed)–Titan Spine, LLC announced today that it began limited market release of its ENDOSKELETON(R) TT system, a new transforaminal lumbar interbody fusion (TLIF) device. The ENDOSKELETON(R) TT received 510(k) clearance from…
Devices, Orthopaedic, Neurosurgery
Titan Spine, ENDOSKELETON TT, lumbar interbody fusion
Posts on ‘August 5th, 2009’
Titan Spine’s Interbody Device Participates in the Fusion Process
Blacktoe Pathology Expands Executive Team With New CEO and VP of Revenue in Anticipation of Commercial Product Launch
PORTLAND, OR., Aug 5 –(HSMN NewsFeed)– Blacktoe Clinical announces the expansion of their Executive Team with the recent hiring of Mike Temple as Chief Executive Officer, and earlier this year, Scott Ronk as Vice President of Sales, Marketing and Business…
Devices, Personnel
Blacktoe Pharmaceutical, SonicEye
London’s Barts Hospital Selects Varian Equipment to Offer Advanced Radiotherapy to More Cancer Patients
LONDON, Aug. 5 (HSMN NewsFeed) — Developers behind an ambitious project to redevelop one of London’s leading cancer centers have ordered four new radiotherapy treatment machines from Varian Pharma Systems (NYSE: VAR ). Barts and The London NHS Trust is…
Devices, Oncology
Varian Pharmaceutical, radiotherapy, Clinac , linear accelerator, RapidArc
Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients
SAN DIEGO, Aug. 5 (HSMN NewsFeed) — Ceregene, Inc. today announced that the Michael J. Fox Foundation will provide partial funds for long-term follow-up testing of patients enrolled in the company’s Phase 2 trial of CERE-120 for Parkinson’s disease. The…
Biopharmaceuticals, Neurology
Ceregene, CERE-120, Parkinson’s disease
Omeros Appoints New Vice President of Medical Development
SEATTLE, Aug. 5 (HSMN NewsFeed) — Omeros Corporation today announced the appointment of Stephen R. Murray, M.D., Ph.D. as Vice President of Clinical Development. Dr. Murray will oversee clinical trial strategies and protocols at Omeros, and currently is…
Biopharmaceuticals, Personnel
Omeros Corp
XDx Completes $14.4 Million Series G Financing
XDx Poised to Achieve Break-Even in 2010 BRISBANE, Calif.–(HSMN NewsFeed)–XDx, Inc., a molecular diagnostics company focused on noninvasive gene expression tests for the monitoring of immune-mediated conditions, today announced the completion of a Ser…
Diagnostics, Venture Capital
XDx, molecular diagnostics, personalized medicine
Bioniche Announces Resignation of its CFO
BELLEVILLE, ON, Aug. 5 (HSMN NewsFeed) - Bioniche Life Sciences Inc. (TSX: BNC ), a research-based, technology-driven Canadian biopharmaceutical company, today announced that its Chief Financial Officer, Patrick Montpetit, is resigning his job effec…
Biopharmaceuticals, Personnel
Bioniche Life Sciences
Merck and Schering-Plough Resolve Previously Disclosed Civil Class Action Lawsuits Related to VYTORIN(R) (ezetimibe/simvastatin) and ZETIA(R) (ezetimibe)
WHITEHOUSE STATION, N.J. & KENILWORTH, N.J.–(HSMN NewsFeed)–Merck & Co., Inc., Schering-Plough Corporation and the companies’ cholesterol joint venture, Merck/Schering-Plough Pharmaceuticals (MSP), today announced that they have entered into agreements t…
Biopharmaceuticals, Cardiology, Litigation
Merck, Schering-Plough, VYTORIN, ezetimibe, simvastatin, ZETIA, ezetimibe
Anesiva, Inc. and Arcion Therapeutics Announce Merger Agreement
Creates New Company Focused on Targeted Pain Therapeutics that Address Large Markets With Unmet Needs Telcon Scheduled for Wednesday, August 5, 2009 at 8:30 AM EDT SOUTH SAN FRANCISCO, Calif., and BALTIMORE, Aug. 5 (HSMN NewsFeed) — Anesi…
Biopharmaceuticals, Mergers & Acquisitions, Personnel
Anesiva, Arcion Therapeutics
